Anthony G. Quinn - Mar 11, 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
President & CEO, Director
Signature
/s/ James Kastenmayer, by power of attorney
Stock symbol
AGLE
Transactions as of
Mar 11, 2022
Transactions value $
$280,943
Form type
4
Date filed
3/15/2022, 06:32 PM
Previous filing
Feb 22, 2022
Next filing
Mar 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGLE Common Stock Purchase $71.8K +34.8K +10.58% $2.06 364K Mar 11, 2022 Direct F1
transaction AGLE Common Stock Purchase $130K +67.5K +18.56% $1.93 431K Mar 14, 2022 Direct F2
transaction AGLE Common Stock Purchase $78.9K +42.4K +9.84% $1.86 473K Mar 15, 2022 Direct F3
holding AGLE Common Stock 266K Mar 11, 2022 By trusts F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.995 to $2.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F2 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.93 per share, inclusive.
F3 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.89 to $2.00 per share, inclusive.
F4 Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts.